Literature DB >> 18079685

Human corneal epithelial cell proliferation by epiregulin and its cross-induction by other EGF family members.

Shin-ichi Morita1, Yuji Shirakata, Atsushi Shiraishi, Yuko Kadota, Koji Hashimoto, Shigeki Higashiyama, Yuichi Ohashi.   

Abstract

PURPOSE: To investigate the effects of epiregulin, a newly identified member of the epidermal growth factor (EGF) family, on the proliferation of human corneal epithelial cells (HCECs).
METHODS: The proliferation of HCECs was determined by cell counting and BrdU incorporation assays at specific times after exposure to different concentrations of human recombinant epiregulin (0 to 20 ng/ml). Immunohistochemical staining was used to localize epiregulin in cadaveric corneas. RT-PCR and real-time PCR were used to determine the expression levels of epiregulin in cultured and cadaveric HCECs. To examine the interaction between epiregulin and epidermal growth factor receptors (EGFRs), the phosphorylation of ErbB1 and ERK1/ERK2 (ERK1/2) was estimated by western blot analysis in the presence or absence of AG1478, a specific inhibitor of EGFR kinase activity. To search for cross-induction of epiregulin by other EGF family members, the expressions of EGF, heparin-binding epidermal growth factor-like growth factor (HB-EGF), amphiregulin (AR), and transforming growth factor-alpha (TGF-alpha) mRNA were determined by real-time PCR in the presence of 10 ng/ml of epiregulin. Conversely, the expression of epiregulin was also determined following the incubation of HCECs with 10 nM of either of EGF, HB-EGF, TGF-alpha, or AR.
RESULTS: The mRNA of epiregulin was expressed in cultured HCECs and HCECs obtained from cadaveric eyes. Epiregulin was strongly detected in the limbal epithelium and basal epithelium of the peripheral cornea, but it was weakly detected in the central corneal epithelium. HCECs proliferated in the presence of epiregulin in a dose-dependent manner as detected by an increase in cell numbers or in BrdU incorporation. When HCECs were incubated with exogenous epiregulin, the expression of the mRNA of epiregulin was upregulated as detected by real-time PCR, and the phosphorylation of ErbB1 and ERK1/2 was upregulated in a dose-dependent manner as shown by western blot analysis. These upregulations were inhibited by AG1478, a specific inhibitor of EGFR kinase activity. Epiregulin increased the expression of HB-EGF and AR, while TGF-alpha, HB-EGF, AR, and EGF increased the expression of epiregulin in HCECs.
CONCLUSIONS: These findings indicate that epiregulin played an autocrine role in the proliferation of HCECs presumably through cross-induction with other EGF family members.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18079685

Source DB:  PubMed          Journal:  Mol Vis        ISSN: 1090-0535            Impact factor:   2.367


  23 in total

Review 1.  Epiregulin: roles in normal physiology and cancer.

Authors:  David J Riese; Richard L Cullum
Journal:  Semin Cell Dev Biol       Date:  2014-03-12       Impact factor: 7.727

2.  Epiregulin can promote proliferation of stem cells from the dental apical papilla via MEK/Erk and JNK signalling pathways.

Authors:  Y Cao; D S Xia; S R Qi; J Du; P Ma; S L Wang; Z P Fan
Journal:  Cell Prolif       Date:  2013-07-06       Impact factor: 6.831

Review 3.  Growth factors and corneal epithelial wound healing.

Authors:  Fu-Shin X Yu; Jia Yin; Keping Xu; Jenny Huang
Journal:  Brain Res Bull       Date:  2009-09-04       Impact factor: 4.077

Review 4.  Progress in corneal wound healing.

Authors:  Alexander V Ljubimov; Mehrnoosh Saghizadeh
Journal:  Prog Retin Eye Res       Date:  2015-07-18       Impact factor: 21.198

5.  Multipathway kinase signatures of multipotent stromal cells are predictive for osteogenic differentiation: tissue-specific stem cells.

Authors:  Manu O Platt; Catera L Wilder; Alan Wells; Linda G Griffith; Douglas A Lauffenburger
Journal:  Stem Cells       Date:  2009-11       Impact factor: 6.277

Review 6.  Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer.

Authors:  Akiko Kubo; Hironobu Hashimoto; Naoki Takahashi; Yasuhide Yamada
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

Review 7.  Limbal stem cells: identity, developmental origin, and therapeutic potential.

Authors:  Gabriel Gonzalez; Yuzuru Sasamoto; Bruce R Ksander; Markus H Frank; Natasha Y Frank
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2017-11-03       Impact factor: 5.814

8.  Sustained epidermal growth factor receptor levels and activation by tethered ligand binding enhances osteogenic differentiation of multi-potent marrow stromal cells.

Authors:  Manu O Platt; Arian J Roman; Alan Wells; Douglas A Lauffenburger; Linda G Griffith
Journal:  J Cell Physiol       Date:  2009-11       Impact factor: 6.384

9.  New technique for culturing corneal epithelial cells of normal mice.

Authors:  Takeshi Kobayashi; Ryuji Yoshioka; Atsushi Shiraishi; Yuichi Ohashi
Journal:  Mol Vis       Date:  2009-08-14       Impact factor: 2.367

10.  Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker.

Authors:  Kusumawadee Utispan; Peti Thuwajit; Yoshimitsu Abiko; Komgrid Charngkaew; Anucha Paupairoj; Siri Chau-in; Chanitra Thuwajit
Journal:  Mol Cancer       Date:  2010-01-24       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.